-
Product Insights
Majdanpek (MS) Mine
The Majdanpek (MS) Mine is a copper mine in Serbia. It is currently in operation. Empower your strategies with our Majdanpek (MS) Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MS-2001 in Brain Hemorrhage
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MS-2001 in Brain Hemorrhage Drug Details: MS-2001 is under development for the treatment of intraventricular...
-
Product Insights
NewLikelihood of Approval Analysis for Secondary Progressive Multiple Sclerosis (SPMS)
Overview How likely is it that the drugs in Secondary Progressive Multiple Sclerosis (SPMS) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Secondary Progressive Multiple Sclerosis (SPMS) Overview Secondary progressive multiple...
-
Product Insights
NewLikelihood of Approval Analysis for Multiple Sclerosis
Overview How likely is it that the drugs in Multiple Sclerosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Multiple Sclerosis Overview Multiple sclerosis (MS) is an autoimmune disease in which...
-
Product Insights
NewLikelihood of Approval Analysis for Primary Progressive Multiple Sclerosis (PPMS)
Overview How likely is it that the drugs in Primary Progressive Multiple Sclerosis (PPMS) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Primary Progressive Multiple Sclerosis (PPMS) Overview Primary progressive multiple...
-
Product Insights
MS Noboribetsu Solar PV Park
MS Noboribetsu Solar PV Park is a solar PV project located in Hokkaido, Japan. The project is currently active. Empower your strategies with our MS Noboribetsu Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability...
-
Product Insights
Kaminoboribetsu MS Solar PV Park
Kaminoboribetsu MS Solar PV Park is a solar PV project located in Hokkaido, Japan. The project came online in 2019. Empower your strategies with our Kaminoboribetsu MS Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data...
-
Product Insights
NewLikelihood of Approval Analysis for Relapsing Remitting Multiple Sclerosis (RRMS)
Overview How likely is it that the drugs in Relapsing Remitting Multiple Sclerosis (RRMS) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Relapsing Remitting Multiple Sclerosis (RRMS) Overview Relapsing-remitting multiple sclerosis...
-
Product Insights
NewLikelihood of Approval Analysis for Relapsing Multiple Sclerosis (RMS)
Overview How likely is it that the drugs in Relapsing Multiple Sclerosis (RMS) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Relapsing Multiple Sclerosis (RMS) Overview Multiple sclerosis (MS) is the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MS-1901 in Hypoxic-Ischemic Encephalopathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. MS-1901 in Hypoxic-Ischemic Encephalopathy Drug Details: MS-1901 is under development for the treatment of hypoxic...